PRISMS is dedicated to providing information and support to families of persons with Smith-Magenis Syndrome (SMS), sponsoring research and fostering partnerships with professionals to increase awareness and understanding of SMS.

PRISMS has compiled a list of resources that we hope you will find helpful as you cope with the impact of the coronavirus pandemic.

Please see the COVID-19 Resources page for more information.

Newly Diagnosed?

Are you associated with someone who has been newly diagnosed with Smith-Magenis Syndrome?

What You Should Know

You are embarking on a difficult journey, but one that is rewarding.
You will grieve when your child struggles, but you will revel in their accomplishments.

What is SMS?

Smith-Magenis syndrome (SMS) is a rare neurobehavioral disorder characterized by a recognizable pattern of physical, behavioral, and developmental features. It is caused by particular genetic changes on chromosomal region 17p11.2, which contains the gene RAI1. MORE >

What Treatment is Available?

There are no medications that can “cure” SMS or eliminate the core symptoms. However, there are medications that can help some people with SMS function better. For example, medication might help manage high energy levels, inability to focus, or seizures. MORE >

How Rare is SMS?

Although the exact incidence is not known, it is estimated that SMS occurs in about 1/15,000 to 1/25,000 births. SMS is under-diagnosed, but as awareness of the syndrome increases, the number of people identified grows each year. MORE >

How is SMS Diagnosed?

The diagnosis of Smith-Magenis Syndrome (SMS) is usually confirmed through a clinical blood test called a chromosome analysis. Diagnosis can also be made through a cytogenetic test and FISH (fluorescence in situ hybridization) or by chromosome microarray analysis (CGH). MORE >

Please Donate

Our continued efforts depend on donations and gifts from people like you. Won’t you help?

Donate Now

Recent SMS News

  • Moving Care of SMS Forward

    By: Maggie Miller On December 1, 2020, the Food and Drug Administration (FDA) approved the use of HETLIOZ® (tasimelteon) capsule and liquid formulations for the treatment of adults and children, respectively, with nighttime sleep disturbances…

    See More >
  • My Sister’s Swing 

    By: Haley Rupp My name is Haley and I am 23 years old, the youngest of three children. My oldest sister, Kristen, is 29, and right in the middle of us is Carley, who is…

    See More >